NCT02707120View on ClinicalTrials.gov

Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) Eye-drops in the Treatment of Neurotrophic Keratitis

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 4, 2018

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2020

Conditions
Neurotrophic Keratitis
Interventions
DRUG

PRGF-Endoret

Active treatment will be PRP eye drops obtained by the PRGF-Endoret system.

DRUG

Artificial tears eye-drops

Artificial tear moisturizing eyedrops (Hidrathea®, Nacl 0.9 % solution without preservatives).

Trial Locations (4)

Unknown

Instituto Clínico Quirúrgico de Oftalmología (ICQO), Bilbao

Instituto Oftalmológico Fernández-Vega, Oviedo

Instituto de Microcirugía Ocular (IMO), Barcelona

Hospital Ramón y Cajal, Madrid

Sponsors
All Listed Sponsors
lead

Biotechnology Institute IMASD

INDUSTRY